important information for the patient.
Ivohart (ivabradine) is a heart medicine used to treat:
About stable angina pectoris (usually referred to as "angina")
Stable angina pectoris is a heart disease that occurs when the heart muscle does not receive enough oxygen. This disease usually appears in people between 40 and 50 years old.
The most common symptom of angina pectoris is chest pain or discomfort. Angina pectoris occurs more frequently with faster heart rate, for example, after exercise, in emotions, in a cold environment, or after a meal. In people with angina pectoris, an accelerated heart rate causes chest pain.
About chronic heart failure
Chronic heart failure is a heart disease that occurs when the heart cannot pump enough blood to the rest of the body. The most common symptoms of heart failure are shortness of breath, fatigue, tiredness, and swelling of the ankles.
How does Ivohart work?
Ivohart works mainly by reducing the heart rate by a few beats per minute. This leads to a reduction in the heart muscle's demand for oxygen, especially in situations where an angina attack is more likely to occur. In this way, Ivohart helps control and reduce the number of angina attacks.
Additionally, since an increased heart rate has a negative effect on heart function and survival in patients with chronic heart failure, the specific action of ivabradine, which reduces heart rate, helps improve heart function and survival in these patients.
Before starting to take Ivohart, the doctor or pharmacist should be consulted:
In case of any of the above situations, the doctor should be informed immediately before taking or during the use of Ivohart.
Ivohart is not intended for use in children and adolescents under the age of 18.
The doctor or pharmacist should be told about all medicines the patient is currently taking or has recently taken, as well as any medicines the patient plans to take.
The doctor should be informed about taking any of the following medicines, as it may be necessary to adjust the dose of Ivohart or closely monitor its use:
Grapefruit juice should be avoided during treatment with Ivohart.
Ivohart should not be taken during pregnancy or when planning to have a child (see "When not to take Ivohart").
The doctor should be consulted in case of pregnancy during the use of Ivohart.
A woman of childbearing age should not take Ivohart unless she uses appropriate methods of contraception (see "When not to take Ivohart").
Ivohart should not be taken during breastfeeding (see "When not to take Ivohart"). The patient should consult a doctor if she is breastfeeding or plans to breastfeed, as breastfeeding should be discontinued if the patient is taking Ivohart.
If the patient is pregnant, breastfeeding, or thinks she may be pregnant, or is planning to have a child, she should consult a doctor or pharmacist before taking this medicine.
Ivohart may cause transient vision disturbances (temporary sensations of seeing strong light in the field of vision, see "Possible side effects"). In case of their occurrence, caution should be exercised when driving or operating machines, especially in situations where there may be sudden changes in lighting, especially when driving at night.
If the patient has previously been diagnosed with intolerance to some sugars, they should contact their doctor before taking this medicine.
The medicine contains less than 1 mmol (23 mg) of sodium per tablet, which means the medicine is considered "sodium-free".
This medicine should always be taken as directed by the doctor or pharmacist. In case of doubts, the doctor or pharmacist should be consulted.
Ivohart should be taken during meals.
If the patient is being treated for stable angina pectoris
The initial dose should not be higher than one 5 mg tablet of Ivohart twice a day.
If the patient still has symptoms of angina pectoris and tolerates the dose of 5 mg twice a day well, the dose may be increased. The maintenance dose should not be higher than 7.5 mg twice a day. The doctor will prescribe the appropriate dose for the patient. The usual dose is one tablet in the morning and one tablet in the evening. In some cases (e.g., if the patient is elderly), the doctor may prescribe half the dose, i.e., half a 5 mg tablet of Ivohart 5 mg (which corresponds to 2.5 mg of ivabradine) in the morning and half a 5 mg tablet in the evening.
If the patient is being treated for chronic heart failure
The usual initial dose is one 5 mg tablet of Ivohart twice a day. If necessary, the dose can be increased to one 7.5 mg tablet of Ivohart twice a day.
The doctor will determine the appropriate dose for the patient. The usual dose is one tablet in the morning and one tablet in the evening. In some cases (e.g., if the patient is elderly), the doctor may recommend half the dose, i.e., half a 5 mg tablet of Ivohart 5 mg (which corresponds to 2.5 mg of ivabradine) in the morning and half a 5 mg tablet in the evening.
After taking a large dose of Ivohart, shortness of breath or fatigue may occur, as the heart rate slows down (bradycardia) excessively. In such a case, the doctor should be consulted immediately.
In case of a missed dose of Ivohart, the next dose should be taken at the usual time. A double dose should not be taken to make up for the missed dose.
Since the treatment of angina pectoris or chronic heart failure is usually long-term, before stopping the use of this medicine, the doctor should be consulted.
If the patient feels that the effect of Ivohart is too strong or too weak, they should consult a doctor or pharmacist.
In case of any further doubts about the use of this medicine, the doctor or pharmacist should be consulted.
Like all medicines, Ivohart can cause side effects, although not everybody gets them.
The frequency of possible side effects listed below is defined as follows:
very common: may affect more than 1 in 10 people;
common: may affect up to 1 in 10 people;
uncommon: may affect up to 1 in 100 people;
rare: may affect up to 1 in 1,000 people;
very rare: may affect up to 1 in 10,000 people;
frequency not known: the frequency cannot be estimated from the available data.
The most common side effects of this medicine are dose-dependent and related to its mechanism of action:
Very common:
vision disturbances (temporary sensations of seeing strong light, most often caused by sudden changes in lighting). These disturbances are also described as an aura, colored flashes, split vision, or multiple images. They usually appear within the first two months of treatment, after which they may recur and disappear during therapy or after treatment.
Common:
changes in heart function (symptoms of slowed heart rate). Symptoms occur especially within the first 2 to 3 months after starting treatment.
Other side effects have also been reported:
Common:
irregular, rapid heartbeats, unusual sensation of heartbeat, uncontrolled blood pressure, headaches, dizziness, and blurred vision (blurred vision).
Uncommon:
palpitations and extra heartbeats, nausea, constipation, diarrhea, abdominal pain, sensation of spinning (dizziness of labyrinthine origin), breathing difficulties (shortness of breath), muscle cramps, and changes in laboratory parameters: high uric acid levels in the blood, increased eosinophil count in the blood (a type of white blood cell), and increased creatinine levels in the blood (a muscle breakdown product), rash, angioedema (symptoms such as a swollen face, swollen tongue or throat, difficulty breathing or swallowing), low blood pressure, fainting, feeling of fatigue, feeling of weakness, abnormal ECG recording, double vision, impaired vision.
Rare:
hives, itching, skin redness, malaise.
Very rare:
irregular heartbeat.
If any side effects occur, including any side effects not listed in this leaflet, the doctor or pharmacist should be informed, or the nurse.
Side effects can be reported directly to the Department of Monitoring of Adverse Reactions to Medicinal Products of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products,
Jerozolimskie Avenue 181C, 02-222 Warsaw, Tel.: +48 22 49 21 301, Fax: +48 22 49 21 309,
Website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder.
By reporting side effects, more information can be collected on the safety of the medicine.
The medicine should be stored out of sight and reach of children.
The medicine should not be used after the expiry date stated on the carton and blister after the abbreviation EXP. The expiry date refers to the last day of the month.
There are no special precautions for storage.
Medicines should not be disposed of via wastewater or household waste. The pharmacist should be asked how to dispose of medicines that are no longer used. This will help protect the environment.
Tablet core:
Lactose monohydrate
Microcrystalline cellulose
Sodium carmellose
Colloidal anhydrous silica
Magnesium stearate
Coating:
Hypromellose 6 cp (E464)
Titanium dioxide (E171)
Macrogol 6000 (E1521)
Magnesium stearate (E470b)
Glycerol (E422)
Ivohart: a white, oval, biconvex coated tablet with a score line to facilitate breaking the tablet and with the marking "5" on one side, smooth on the other side.
Ivohart: a white, round, biconvex coated tablet with the marking "7.5" on one side, smooth on the other side.
Tablets are available in packs (aluminum/aluminum blisters, in a cardboard box) of 14, 28, 56, 84, 98, 100, or 112 tablets.
Not all pack sizes may be marketed.
Bausch Health Ireland Limited
3013 Lake Drive
Citywest Business Campus
Dublin 24, D24PPT3
Ireland
Genepharm S.A.
18th km Marathon Avenue
15351 Pallini, Attiki
Greece
Date of last revision of the leaflet:11/2020
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.